1. Home
  2. AKBA vs EIG Comparison

AKBA vs EIG Comparison

Compare AKBA & EIG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AKBA
  • EIG
  • Stock Information
  • Founded
  • AKBA 2007
  • EIG 2000
  • Country
  • AKBA United States
  • EIG United States
  • Employees
  • AKBA N/A
  • EIG N/A
  • Industry
  • AKBA Biotechnology: Pharmaceutical Preparations
  • EIG Property-Casualty Insurers
  • Sector
  • AKBA Health Care
  • EIG Finance
  • Exchange
  • AKBA Nasdaq
  • EIG Nasdaq
  • Market Cap
  • AKBA 861.7M
  • EIG 986.1M
  • IPO Year
  • AKBA 2014
  • EIG 2007
  • Fundamental
  • Price
  • AKBA $2.88
  • EIG $41.82
  • Analyst Decision
  • AKBA Strong Buy
  • EIG Strong Buy
  • Analyst Count
  • AKBA 5
  • EIG 1
  • Target Price
  • AKBA $6.90
  • EIG $58.00
  • AVG Volume (30 Days)
  • AKBA 2.9M
  • EIG 204.0K
  • Earning Date
  • AKBA 11-06-2025
  • EIG 10-30-2025
  • Dividend Yield
  • AKBA N/A
  • EIG 3.07%
  • EPS Growth
  • AKBA N/A
  • EIG N/A
  • EPS
  • AKBA N/A
  • EIG 4.10
  • Revenue
  • AKBA $203,733,000.00
  • EIG $889,500,000.00
  • Revenue This Year
  • AKBA $43.91
  • EIG $0.86
  • Revenue Next Year
  • AKBA $32.09
  • EIG $0.80
  • P/E Ratio
  • AKBA N/A
  • EIG $10.19
  • Revenue Growth
  • AKBA 16.75
  • EIG 2.32
  • 52 Week Low
  • AKBA $1.26
  • EIG $38.19
  • 52 Week High
  • AKBA $4.08
  • EIG $54.44
  • Technical
  • Relative Strength Index (RSI)
  • AKBA 47.89
  • EIG 43.51
  • Support Level
  • AKBA $2.83
  • EIG $41.84
  • Resistance Level
  • AKBA $3.02
  • EIG $42.94
  • Average True Range (ATR)
  • AKBA 0.12
  • EIG 0.57
  • MACD
  • AKBA 0.03
  • EIG 0.03
  • Stochastic Oscillator
  • AKBA 56.94
  • EIG 12.39

About AKBA Akebia Therapeutics Inc.

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.

About EIG Employers Holdings Inc

Employers Holdings Inc is a provider of workers' compensation insurance and services focused on small and mid-sized businesses engaged in low-to-medium hazard industries. Its customers are employers, and the insurance premiums that those employers pay to account for company revenue. Substantially all of the remaining revenue is generated through investments. The company operates exclusively in the United States, and it generates more than half of its business in California. By industry, the company has exposure to restaurants, which account for roughly a fourth of the total premiums the company earns. It operates as a single reportable segment, Insurance Operations, through its wholly owned subsidiaries.

Share on Social Networks: